Methods and compositions for the antiviral use of synthetic lysine analogs and mimetics

Abstract

A method for treatment, prevention, or reduction of one-time or recurring viral outbreaks, for suppression of development or growth of chronic viral infections, or for prevention or treatment of viral infections, the method including, administering a synthetic lysine analog or mimetic, where the synthetic lysine analog or mimetic antagonizes or competes with an amino acid or other biological agent required by a virus to replicate or spread. Additionally, a composition to treat, prevent, or reduce one-time or recurrent viral outbreaks, suppress development or growth of chronic viral infections, or to prevent or treat viral infections, the composition including, a synthetic lysine analog or mimetic, where the synthetic lysine analog or mimetic antagonizes or competes with an amino acid or other biological agent required by a virus to replicate or spread.

1 . A method for treatment of an infection, the method comprising:
 topically administering a solution consisting of 3 to 30% (w/v) of a synthetic lysine analog or mimetic to a subject suffering from an infection caused by a common cold virus, an influenza virus, or other transient respiratory virus, wherein the topical administration is the only mode of administration of the synthetic lysine analog or mimetic to the subject, wherein the synthetic lysine analog or mimetic is tranexamic acid, epsilon-aminocaproic acid (EACA), or AZD 6564, and wherein the synthetic lysine analog or mimetic is the only antiviral agent administered to the subject; and   treating the mouth, nose, throat, pharynx or nasal passage of the subject to which the synthetic lysine analog or mimetic is topically applied.   
     
     
         2 - 5 . (canceled) 
     
     
         6 . The method of  claim 1 , wherein the solution is an aqueous solution. 
     
     
         7 . (canceled) 
     
     
         8 . The method of  claim 1 , wherein the topically administering involves applying the synthetic lysine analog or mimetic as a spray, mist, or aerosol. 
     
     
         9 . The method of  claim 1 , wherein the topically administering involves applying the synthetic lysine analog or mimetic as part of a vehicle which adapts to human skin or mucous membrane. 
     
     
         10 - 13 . (canceled) 
     
     
         14 . The method of  claim 1 , wherein the topically administering of the synthetic lysine analog or mimetic occurs at least once a day. 
     
     
         15 . The method of  claim 1 , wherein the topically administering of the synthetic lysine analog or mimetic occurs on a weekly or semiweekly basis. 
     
     
         16 . The method of  claim 1 , wherein the topically administering of the synthetic lysine analog or mimetic occurs on a monthly or semimonthly basis. 
     
     
         17 - 18 . (canceled) 
     
     
         19 . The method of  claim 1 , wherein the synthetic lysine analog or mimetic is administered with at least one amino acid. 
     
     
         20 . The method of  claim 1 , wherein the synthetic lysine analog or mimetic is administered with at least one other natural or synthetic amino acid analog or mimetic. 
     
     
         21 . The method of  claim 1 , wherein the topically administering involves applying the synthetic lysine analog or mimetic as a swab or mouth wash. 
     
     
         22 . The method of  claim 1 , wherein the other transient respiratory virus is at least one of respiratory syncytial virus, parainfluenza viruses, metapneumovirus, rhinovirus, coronaviruses, adenoviruses, or bocaviruses.